MiNK Therapeutics (NASDAQ:INKT) Earns “Buy” Rating from HC Wainwright

MiNK Therapeutics (NASDAQ:INKT)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $35.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 232.38% from the stock’s previous close.

Separately, Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $35.00.

MiNK Therapeutics Stock Up 0.1%

INKT stock opened at $10.53 on Wednesday. MiNK Therapeutics has a 52-week low of $6.34 and a 52-week high of $76.00. The firm has a market cap of $49.39 million, a P/E ratio of -3.48 and a beta of 0.35. The company’s 50-day simple moving average is $10.95 and its 200-day simple moving average is $12.24.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.14. On average, analysts anticipate that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MiNK Therapeutics

A hedge fund recently bought a new stake in MiNK Therapeutics stock. DRW Securities LLC bought a new stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.